MRD is a hot topic in CLL; with a multitude of new agents coming through and being used in different combinations, MRD could provide a key strategy to direct treatment decisions1-3.

MRD is one of the strongest predictive markers in CLL4-7. With further research, MRD status may potentially be used to determine treatment duration, theoretically allowing treatment cessation for those who are MRD negative7. A key question to address is what tissue to look at; the peripheral blood or bone marrow6.

  1. Böttcher S, Hallek M, Ritgen M, et al. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin North Am. 2013 Apr; 27(2): 267-88.
  2. Thompson PA, Peterson CB, Strati P, et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 Apr 17. [Epub ahead of print].
  3. Ghia P, Rawstron A. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia. 2018 Jun; 32(6): 1307-1316.
  4. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016 Jan 21; 127(3): 279-86.
  5. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016 Dec 15; 128(24): 2770-2773.
  6. VJHemOnc (2018). MRD as a marker for depth of remission in CLL. Available at: https://www.vjhemonc.com/video/hdcsktpthve-mrd-as-a-marker-for-depth-of-remission-in-cll (Accessed: 03 July 2018).
  7. VJHemOnc (2018). The importance of MRD negativity as a predictive marker in CLL. Available at: https://www.vjhemonc.com/video/whf8cysb6c8-the-importance-of-mrd-negativity-as-a-predictive-marker-in-cll (Accessed: 03 July 2018).
View overview page

MRD and Chronic Lymphocytic Leukemia

MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content

MRD and Chronic Lymphocytic Leukemia

MRD is a hot topic in CLL; with a multitude of new agents coming through and being used in different combinations, MRD could provide a key strategy to direct treatment decisions1-3.

MRD is one of the strongest predictive markers in CLL4-7. With further research, MRD status may potentially be used to determine treatment duration, theoretically allowing treatment cessation for those who are MRD negative7. A key question to address is what tissue to look at; the peripheral blood or bone marrow6.

  1. Böttcher S, Hallek M, Ritgen M, et al. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin North Am. 2013 Apr; 27(2): 267-88.
  2. Thompson PA, Peterson CB, Strati P, et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 Apr 17. [Epub ahead of print].
  3. Ghia P, Rawstron A. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia. 2018 Jun; 32(6): 1307-1316.
  4. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016 Jan 21; 127(3): 279-86.
  5. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016 Dec 15; 128(24): 2770-2773.
  6. VJHemOnc (2018). MRD as a marker for depth of remission in CLL. Available at: https://www.vjhemonc.com/video/hdcsktpthve-mrd-as-a-marker-for-depth-of-remission-in-cll (Accessed: 03 July 2018).
  7. VJHemOnc (2018). The importance of MRD negativity as a predictive marker in CLL. Available at: https://www.vjhemonc.com/video/whf8cysb6c8-the-importance-of-mrd-negativity-as-a-predictive-marker-in-cll (Accessed: 03 July 2018).
View overview page
MRD content on VJHemOnc.com is sponsored by AbbVie Ltd and Adaptive Biotechnologies. The companies have no influence over the production of the content